On November 4, 2016, Biocept, Inc. (the

Company

) voluntarily terminated the common stock purchase agreement (the

Purchase Agreement

) that the Company entered into on December 21, 2015, with Aspire Capital Fund, LLC (

Aspire Capital

).Pursuant to the Purchase Agreement, upon the terms and subject to the conditions and limitations set forth therein, Aspire Capital was committed to purchase up to an aggregate of $15.0 million of shares of the Companys common stock over the 30-month term of the Purchase Agreement.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized .

BIOCEPT, INC.

Dated: November 4, 2016

By:

/s/ Michael W. Nall

Name:

Michael W. Nall

Title:

President and Chief Executive Officer

makes a similar move, sign up!

Other recent filings from the company include the following:

General form for registration of securities under the Securities Act of 1933 - Nov. 21, 2017
General form for registration of securities under the Securities Act of 1933 - Nov. 17, 2017
Biocept Reports Third Quarter 2017 Financial Results - Nov. 9, 2017

Auto Refresh

Feedback